Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care
Brief Summary: Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two.

Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: Iron-folic acid and mebendazole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole + Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron-folic acid and mebendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Mebendazole; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Mebendazole + Multivitamin; Assigned to Arm(s): 4
B: Arm Label: Alternative SoF; Type: EXPERIMENTAL; Interventions: Other: Alternative summary of findings table format | Arm Label: Current SoF; Type: ACTIVE_COMPARATOR; Interventions: Other: Current summary of findings table format | Intervention Type: OTHER; Name: Alternative summary of findings table format; Assigned to Arm(s): Alternative SoF | Intervention Type: OTHER; Name: Current summary of findings table format; Assigned to Arm(s): Current SoF
C: Arm Label: Deworming at 12 months of age; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole, Other: Usual care | Arm Label: Deworming at 18 months of age; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole, Other: Usual care | Arm Label: Deworming at 12 and 18 months of age; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole, Other: Usual care | Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: DRUG; Name: Mebendazole; Assigned to Arm(s): Deworming at 12 and 18 months of age, Deworming at 12 months of age, Deworming at 18 months of age | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Deworming at 12 and 18 months of age, Deworming at 12 months of age, Deworming at 18 months of age, Usual care
D: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C